AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 122 min read$ALHC

Alignment Healthcare (ALHC) CEO stock sales tied to taxes and trading plan

Alignment Healthcare (ALHC) CEO John E. Kao sold 557,870 shares. On September 11, 2026, he sold 385,270 shares at $12.68 per share to cover tax obligations. On September 10, 2026, a trust associated with Kao sold 172,600 shares at $12.96 per share under a 10b5-1 trading plan. Kao held 1,223,473 shares directly and 618,166 shares indirectly post-sales.

Original reporting
stocktitan.net
Published Sep 12, 2026, 12:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 5:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ALHC
Bearish
medium confidence
Mentioned
$ALHC
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ALHCBearishLow
01

Why it matters

The disclosure provides fresh insider activity data, which may influence short‑term trading sentiment.

02

Market read

Primary insider sale filing; modest materiality but new information for traders.

03

What to watch

The 10b5-1 plan pre-schedules sales, reducing the informational content of the transaction.

Relevance 6/10Novelty 5/10Timing: post-trade today

Background

Alignment Healthcare filed a Form 4 reporting the CEO's stock sales to cover tax obligations and under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$ALHCBearishMedium confidence
Context

CEO John E. Kao sold 557,870 shares of Alignment Healthcare on Sep 10-11, 2026, totaling about $7.1M, disclosed via a Form 4 filing.

Expected impact

Potential short-term dip of 1-2% as the market digests the sale.

Evidence & confidence

Insider sales, especially by a CEO, are often viewed as a negative signal, but the transaction size is modest relative to market cap.

Market effects

Sector

Limited; reflects typical insider activity in the healthcare services sector.

Regional

Minimal impact on broader US market.

Global

None beyond the specific stock.

Counterpoint

What could challenge this read

The sale could be routine tax withholding and not indicative of future performance.

Key entities

  • individual
    John E. Kao

    CEO and director of Alignment Healthcare

  • company
    Alignment Healthcare, Inc.

    US‑listed healthcare services firm (ticker ALHC)

Read at source← All news

Related articles

SEP 16
$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

seekingalpha.com1 min
SEP 15
$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min
SEP 15
$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

stocktwits.com2 min
SEP 10
$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min
AUG 18
$ALHCMed

Alignment Health seeks to have former exec's whistleblower suit tossed

Alignment Healthcare and executives filed to dismiss a whistleblower suit by former exec Hakan Kardes, who alleges earnings were artificially boosted for higher bonuses. The company claims Kardes resigned voluntarily and his claims are false. Kardes says he was forced out after reporting accounting irregularities, affecting EBITDA and executive bonuses. Shares dropped initially but rebounded.

fiercehealthcare.com5 min
AUG 12
$ALHCMed

Alignment Healthcare (ALHC) Stock Drops 16.7% After Whistleblower Accounting Allegations Trigger Securities Investigation

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations at Alignment Healthcare, Inc. (NASDAQ: ALHC) after a whistleblower complaint alleging accounting irregularities that allegedly inflated previously reported and projected results. The complaint cites operating expenses allegedly misclassified as capital expenditures, affecting Adjusted EBITDA. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.

kalkine.ca3 min